Antibe Therapeutics

Antibe Therapeutics is a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology.[1] Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.[2] On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug.[3]

Antibe Therapeutics Inc.
Publicly traded corporation
Traded asTSX-V: ATE
IndustryPharmaceuticals
Headquarters
Toronto
,
Canada
Key people
Dan Legault JD, CEO; Alain Wilson, CFO; Dr. John L. Wallace, Chief Scientific Officer; Joseph Stauffer, Chief Medical Officer
Websitewww.antibethera.com

Products

The mechanism of action of Antibe's drugs is the delivery of minute amounts of hydrogen sulfide to sites of inflammation within the human body.[4] Hydrogen sulfide has been shown to enhance the resolution of injury and repair of damage arising from tissue inflammation.[5] Antibe's lead drug, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID). ATB-346 is being developed to address osteoarthritis, although Antibe intends to broaden its application to other types of chronic pain and diseases now treated with NSAIDs. Unlike standard naproxen, ATB-346 does not induce damage to the gastrointestinal tract.[6]

In May 2014, the company announced that it had completed pre-clinical studies on ATB-346.[7] In late June 2014, following approval from Health Canada, the company announced the first human dosing for Phase I of its human clinical trials.[8] In mid-January 2015, the company announced that clinical trials for its ATB-346 were being suspended due to safety concerns; clinical trials were restarted in March 2015.[9]

On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346.[10] On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its International Nonproprietary Name, otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study.[11] The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.[12]

Antibe's products have not yet been approved by the US Food and Drug Administration.

People

Antibe's science advisory board:[13]

Antibe's board of directors:[14]

gollark: Stupid proBielefieldists.
gollark: > All prejudice is based on eye technology or similar sources of information<@330678593904443393> You can easily be prejudiced through the internet.
gollark: With eye technology.
gollark: You can just see they are struggling to walk down the staircase.
gollark: Although I suppose the decision to be in an alleyway with a knife and hood is under your control.

References
  1. http://www.antibethera.com
  2. https://www.bloomberg.com/research/stocks/news/article.asp?docKey=600-201602021810BIZWIRE_USPRX____BW6697-1&ex=true&ticker=MNK
  3. https://www.acsh.org/news/2020/08/05/antibes-non-opioid-pain-drug-otenaproxesul-looks-good-phase-iib-trials-14951
  4. https://antibethera.com/science/why-h2s/
  5. "H2S and Inflammation: An Overview". Handb Exp Pharmacol: 165–180. 2015. doi:10.1007/978-3-319-18144-8_8. PMID 26162834.
  6. British Journal of Pharmacology "A proof-of-concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide-releasing anti-inflammatory drug". Br J Pharmacol. 177 (4): 769–777. February 2019. doi:10.1111/bph.14641. PMID 30834513.
  7. https://www.wsj.com/article/PR-CO-20140505-901386.html
  8. http://www.marketwatch.com/story/antibe-therapeutics-announces-first-human-dose-of-atb-346-in-phase-i-clinical-trial-2014-06-26
  9. https://antibethera.com/news/antibe-therapeutics-provides-an-update-on-its-data-review-and-corporate-strategy/
  10. https://antibethera.com/news/antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-for-lead-pain-drug-atb-346/
  11. https://antibethera.com/news/antibe-therapeutics-announces-positive-top-line-data-from-phase-2b-dose-ranging-efficacy-study-for-atb-346/
  12. https://antibethera.com/news/antibe-therapeutics-provides-corporate-update/
  13. https://antibethera.com/about-us/scientific-advisory-board/
  14. https://antibethera.com/about-us/board-of-directors/
  15. http://investorrelations.mastercardintl.com/phoenix.zhtml?c=148835&p=irol-govBio&ID=144740
  16. https://www.gud-knight.com/category/management-team/
  17. https://marsdd.com/about/

Official website

  • Biotechnology Focus: The Need for a Safer NSAID: Can Antibe Therapeutics Deliver One?
  • Third International Conference on Medical & Biological Uses of Hydrogen Sulfide
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.